LCM
NPCE icon

Laurion Capital Management’s Neuropace NPCE Stock Holding History

Laurion Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,699
Closed -$273K – 699
2024
Q1 		$273K Hold
20,699
– – ﹤0.01% 455
2023
Q4 		$213K Buy
+20,699
New +$165K ﹤0.01% 424

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laurion Capital Management's NPCE Position: Q2 2024 in Review

Laurion Capital Management sold out of Neuropace (NPCE) in Q2 2024, closing a stake of 20,699 shares — an estimated $273K sold.

Laurion Capital Management first reported a position in NPCE in Q4 2023 and held it in 2 quarters. The position peaked at $273K in Q1 2024. 51 funds tracked by Wall St. Rank hold NPCE as of Q2 2024.

  • Laurion Capital Management reported no remaining Neuropace position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 20,699 Neuropace shares in Q2 2024, an estimated $273K.
  • Laurion Capital Management first reported a position in Neuropace in Q4 2023 and held it in 2 quarters.
  • Laurion Capital Management's Neuropace position peaked at $273K in Q1 2024.
  • 51 funds tracked by Wall St. Rank held Neuropace as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.